64Cu-LLP2A用于PET显像的安全性及剂量学的首次人体评估
本研究在CD-1小鼠中完成单剂[natCu]Cu-LLP2A耐受性与毒性试验,并对3例多发性骨髓瘤患者和6名健康受试者进行64Cu-LLP2A PET/CT或PET/MRI显像以评估生物分布、药代动力学和辐射剂量学。64Cu-LLP2A人体有效剂量为0.036±0.006 mSv/MBq,脾脏器官摄取最高为0.142±0.034 mSv/MBq,人体受试者未见与药物相关的临床或实验室不良事件。
要点
- 64Cu-LLP2A靶向整合素VLA4,在3例多发性骨髓瘤患者和6名健康受试者中完成首次人体PET显像评估。
- 人体有效剂量为0.036±0.006 mSv/MBq,脾脏器官剂量最高为0.142±0.034 mSv/MBq。
- 注射后4-5小时为最佳显像时间,人体受试者未观察到与64Cu-LLP2A相关的临床或实验室不良事件。
核心结论
- 64Cu-LLP2A在人体中表现出良好的剂量学特征和安全性。
研究设计与样本
- 在CD-1(Hsd:ICR)雄性和雌性小鼠中开展单剂[natCu]Cu-LLP2A耐受性与毒性研究。
- 3例多发性骨髓瘤患者和6名健康受试者在最多3个时间点接受64Cu-LLP2A PET/CT或PET/MRI显像。
- 使用OLINDA软件计算平均器官吸收剂量和有效剂量,并通过细胞结合试验和放射高效液相色谱分析示踪剂生物活性及人血代谢物。
主要发现
- 雄性和雌性CD-1小鼠对150倍质量过量的目标显像剂量耐受良好(未观察到不良反应水平)。
- 人体显像的时间-活性曲线显示示踪剂经肾脏和膀胱快速清除。
- 64Cu-LLP2A人体有效剂量为0.036±0.006 mSv/MBq,脾脏器官摄取最高为0.142±0.034 mSv/MBq,红骨髓在所有组织中驻留时间最长。
- 图像质量分析支持注射后4-5小时为最佳显像时间,所有人体研究用示踪剂的细胞阻断率为82.42%±13.47%(统计学显著)。
- 人血代谢研究证实注射后1小时内产物峰稳定(>90%),人体受试者未观察到与64Cu-LLP2A相关的临床或实验室不良事件。
关键数值与推荐
- 64Cu-LLP2A人体有效剂量为0.036±0.006 mSv/MBq。
- 脾脏器官剂量最高,为0.142±0.034 mSv/MBq。
- 最佳显像时间为注射后4-5小时。
- 所有人体研究用示踪剂的细胞阻断率为82.42%±13.47%。
- 注射后1小时内放射化学产物峰稳定性>90%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
There remains an unmet need for molecularly targeted imaging agents for multiple myeloma (MM). The integrin very late antigen 4 (VLA4), is differentially expressed in malignant MM cells and in pathogenic inflammatory microenvironmental cells. [64Cu]Cu-CB-TE1A1P-LLP2A (64Cu-LLP2A) is a VLA4-targeted, high-affinity radiopharmaceutical with promising utility for managing patients diagnosed with MM. Here, we evaluated the safety and human radiation dosimetry of 64Cu-LLP2A for potential use in MM patients. Methods: A single-dose [natCu]Cu-LLP2A (Cu-LLP2A) tolerability and toxicity study was performed on CD-1 (Hsd:ICR) male and female mice. 64Cu-LLP2A was synthesized in accordance with good-manufacturing-practice-compliant procedures. Three MM patients and six healthy participants underwent 64Cu-LLP2A-PET/CT or PET/MRI at up to 3 time points to help determine tracer biodistribution, pharmacokinetics, and radiation dosimetry. Time-activity curves were plotted for each participant. Mean organ-absorbed doses and effective doses were calculated using the OLINDA software. Tracer bioactivity was evaluated via cell-binding assays, and metabolites from human blood samples were analyzed with analytic radio-high-performance liquid chromatography. When feasible, VLA4 expression was evaluated in the biopsy tissues using 14-color flow cytometry. Results: A 150-fold mass excess of the desired imaging dose was tolerated well in male and female CD-1 mice (no observed adverse effect level). Time-activity curves from human imaging data showed rapid tracer clearance from blood via the kidneys and bladder. The effective dose of 64Cu-LLP2A in humans was 0.036 ± 0.006 mSv/MBq, and the spleen had the highest organ uptake, 0.142 ± 0.034 mSv/MBq. Among all tissues, the red marrow demonstrated the highest residence time. Image quality analysis supports an early imaging time (4-5 h after injection of the radiotracer) as optimal. Cell studies showed statistically significant blocking for the tracer produced for all human studies (82.42% ± 13.47%). Blood metabolism studies confirmed a stable product peak (>90%) up to 1 h after injection of the radiopharmaceutical. No clinical or laboratory adverse events related to 64Cu-LLP2A were observed in the human participants. Conclusion: 64Cu-LLP2A exhibited a favorable dosimetry and safety profile for use in humans.
引用
- Laforest R, Ghai A, Fraum TJ, et al. First-in-Humans Evaluation of Safety and Dosimetry of 64Cu-LLP2A for PET Imaging. J Nucl Med. 2022. PMID: 36008121. doi:10.2967/jnumed.122.264349
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。